Stock comparison
Genmab A/S
Kiniksa Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
KNSA
Kiniksa Pharmaceuticals
Market cap
$4B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | KNSA | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 39D | GMAB |
| Benjamin Graham | 64C | 72D | KNSA |
| Philip Fisher | 48D | 56C | KNSA |
| Peter Lynch | 25F | 36D | KNSA |
| Joel Greenblatt | 76B | 52D | GMAB |
| Charlie Munger | 68C | 39D | GMAB |
| Terry Smith | 71C | 35D | GMAB |
Side-by-side metrics
| Metric | GMAB | KNSA |
|---|---|---|
| Market cap | $16.5B | $4B |
| P/E (TTM) | 6.2x | 61.4x |
| EV/EBIT | 12.0x | 54.7x |
| ROIC (TTM) | 43.78% | 9.56% |
| Gross margin | 93.88% | 54.63% |
| Net margin | 18.23% | 9.69% |
| Revenue CAGR 5y | -18.45% | 104.76% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 61.4x+90%
- ROIC (TTM)43.78%vs 9.56%+78%
- EV/EBIT12.0xvs 54.7x+78%
- Market cap$16.5Bvs $4B+76%
KNSA leads on
- Revenue CAGR 5y104.76%vs -18.45%+118%
- Debt / Equity0.0xvs 0.1x+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.